HCC in the second-line setting. meetinglibrary.asco.org/record/173190/…



Durvalumab +/- tremelimumab in second-line metastatic head and neck cancer not better than SOC chemo (including methotrexate!). Do not use durvalumab. meetinglibrary.asco.org/record/175441/…
 
     
                        

 
    
 
    

 
     
    
 
    
 
    
